Prosecution Insights
Last updated: November 04, 2026
Application No. 19/074,764

SYSTEM AND METHOD FOR FEEDBACK-DRIVEN AUTOMATED DRUG DISCOVERY

Non-Final OA §112§DOUBLEPATENT
Filed
Mar 10, 2025
Priority
Dec 16, 2020 — provisional 63/126,349 +10 more
Examiner
BAKER, CHARLOTTE M
Art Unit
Tech Center
Assignee
Ro5 Inc.
OA Round
1 (Non-Final)
93%
Grant Probability
Favorable
1-2
OA Rounds
4m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 93% — above average
93%
Career Allowance Rate
1023 granted / 1104 resolved
+32.7% vs TC avg
Minimal +0% lift
Without
With
+0.4%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
21 currently pending
Career history
1124
Total Applications
across all art units

Statute-Specific Performance

§101
22.1%
-17.9% vs TC avg
§103
26.7%
-13.3% vs TC avg
§102
29.4%
-10.6% vs TC avg
§112
3.7%
-36.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1104 resolved cases

Office Action

§112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 2 is objected to because of the following informalities: receipt a new drug candidate from a de novo ligand discovery module. Receipt does not seem like the correct term for the claim language. Appropriate correction is required. Claim 8 is objected to because of the following informalities: performing of a secondary assay on the new drug candidate. Should “of” be removed from the claim language?. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-2 and 8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites the limitation "the laboratory equipment controller". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the laboratory API". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the to a bioactivity module". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the laboratory workflow control module". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the instructions". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the appropriate laboratory equipment modules". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the biochemical assay". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the computing device". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the non-volatile data storage device". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the assay procedures". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the primary assay result". There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the binding site". There is insufficient antecedent basis for this limitation in the claim. Claim 2 recites the limitation "the available chemical libraries". There is insufficient antecedent basis for this limitation in the claim. Claim 2 recites the limitation "the roboticized laboratory". There is insufficient antecedent basis for this limitation in the claim. Claim 8 recites the limitation "the automated biochemical assay equipment". There is insufficient antecedent basis for this limitation in the claim. Claim 8 recites the limitation "the primary assay result". There is insufficient antecedent basis for this limitation in the claim. Claim 8 recites the limitation "the known interactions". There is insufficient antecedent basis for this limitation in the claim. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-13 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 12,248,885 (hereinafter ‘885). Although the claims at issue are not identical, they are not patentably distinct from each other because: Current Application ‘885 Claim 1: an iterative physical testing system comprising: automated biochemical assay equipment configured to: receive an amount of a drug candidate molecule and an assay procedure from the laboratory equipment controller, the assay procedure comprising a first parameter; automatically perform an assay of the drug candidate molecule according to the assay procedure to produce an assay result, the assay result comprising an indication as to whether the first parameter has been met by the drug candidate molecule; and where the assay result indicates that the first parameter has been met, send the assay result for that assay to the laboratory API that will send it to the to a bioactivity module along with chemical notation for the drug candidate molecule; and a chemical synthesizer configured to: receive synthesis instructions from the laboratory equipment controller; synthesize a new drug candidate molecule from a supply of chemicals using chemical notation of precursors and synthesis steps provided by a retrosynthesis system; and provide an amount of the new drug candidate molecule to the automated biochemical assay equipment as defined by the laboratory workflow control module; and a laboratory equipment controller that receives the instructions from the laboratory equipment utilization planning module and sends the instructions to the appropriate laboratory equipment modules: the biochemical assay and automated chemical synthesis modules; an artificial intelligence assistance system operating on the computing device, the artificial intelligence assistance system comprising: a chemical database stored in the non-volatile data storage device, the chemical database comprising known interactions of ligands with protein binding sites and rules for retrosynthesis of molecules; a bioactivity module operating on the computing device which causes the computing device to: receive the assay procedures; generate a set of possible drug candidates based on the assay procedures; and send chemical notation for the set of possible drug candidates to the automated biochemical assay equipment for performance of primary assays; a de novo ligand discovery module operating on the computing device which causes the computing device to: receive the primary assay result, the drug candidate molecule, and the binding site from the chemical database; perform one or more interpolations or perturbations of the drug candidate molecule to generate a new drug candidate molecule predicted to meet or exceed the first parameter, the prediction being based on the known interactions of ligands with protein binding sites from the chemical database; and send chemical notation for the new drug candidate molecule to a retrosynthesis system for retrosynthesis; and a retrosynthesis system operating on the computing device which causes the computing device to: receive the chemical notation for the new drug candidate molecule; perform retrosynthesis of the new drug candidate molecule using the rules for retrosynthesis of molecules of the chemical database; and send to the chemical synthesizer chemical notation for precursors and synthesis steps for synthesizing the new drug candidate molecule. Claim 1: an iterative physical testing system comprising: automated biochemical assay equipment configured to: receive an amount of a drug candidate molecule and an assay procedure from the laboratory equipment controller, the assay procedure comprising a first parameter; automatically perform an assay of the drug candidate molecule according to the assay procedure to produce an assay result, the assay result comprising an indication as to whether the first parameter has been met by the drug candidate molecule; and where the assay result indicates that the first parameter has been met, send the assay result for that assay to the laboratory API that will send it to the to a bioactivity module along with chemical notation for the drug candidate molecule; and a chemical synthesizer configured to: receive synthesis instructions from the laboratory equipment controller; synthesize a new drug candidate molecule from a supply of chemicals using chemical notation of precursors and synthesis steps provided by a retrosynthesis system; and provide an amount of the new drug candidate molecule to the automated biochemical assay equipment as defined by the laboratory workflow control module; a computing device comprising a memory, a processor, and a non-volatile data storage device; a laboratory equipment orchestration software operating on the computing device, the laboratory equipment orchestration software comprising: a laboratory API module that communicates with the artificial intelligence assistance system, receives instructions from it, sends back the data and provides information about the available chemical libraries, chemical synthesis capabilities and resources; a laboratory workflow control module that receives instructions from the artificial intelligence assistance system through a laboratory API and defines experimental workflows that the roboticized laboratory will follow, the experimental workflows comprising: receipt of a set of possible drug candidates from a bioactivity module; performance of primary assays on the set of possible drug candidates; sending of primary assay results to an artificial intelligence system for analysis; receipt a new drug candidate from a de novo ligand discovery module; performance of a secondary assay on the new drug candidate; and outputting a result of the secondary assay; a laboratory equipment utilization planning module that receives instructions from the laboratory workflow control module and plans laboratory module use and resource allocation; and a laboratory equipment controller that receives the instructions from the laboratory equipment utilization planning module and sends the instructions to the appropriate laboratory equipment modules: the biochemical assay and automated chemical synthesis modules; an artificial intelligence assistance system operating on the computing device, the artificial intelligence assistance system comprising: a chemical database stored in the non-volatile data storage device, the chemical database comprising known interactions of ligands with protein binding sites and rules for retrosynthesis of molecules; a bioactivity module operating on the computing device which causes the computing device to: receive the assay procedures; generate a set of possible drug candidates based on the assay procedures; and send chemical notation for the set of possible drug candidates to the automated biochemical assay equipment for performance of primary assays; a de novo ligand discovery module operating on the computing device which causes the computing device to: receive the primary assay result, the drug candidate molecule, and the binding site from the chemical database; perform one or more interpolations or perturbations of the drug candidate molecule to generate a new drug candidate molecule predicted to meet or exceed the first parameter, the prediction being based on the known interactions of ligands with protein binding sites from the chemical database; and send chemical notation for the new drug candidate molecule to a retrosynthesis system for retrosynthesis; and a retrosynthesis system operating on the computing device which causes the computing device to: receive the chemical notation for the new drug candidate molecule; perform retrosynthesis of the new drug candidate molecule using the rules for retrosynthesis of molecules of the chemical database; and send to the chemical synthesizer chemical notation for precursors and synthesis steps for synthesizing the new drug candidate molecule. Current Application ‘885 Claim 8: receiving an amount of a drug candidate molecule and an assay procedure, the assay procedure comprising a first parameter; automatically performing an assay of the drug candidate molecule according to the assay procedure to produce an assay result, the assay result comprising an indication as to whether the first parameter has been met by the drug candidate molecule; and where the assay result indicates that the first parameter has been met, sending the assay result for that assay to a bioactivity module along with chemical notation for the drug candidate molecule and a binding site; using a chemical synthesizer, performing the steps of: synthesizing a new drug candidate molecule from a supply of chemicals using chemical notation of precursors and synthesis steps provided by a retrosynthesis system; and providing an amount of the new drug candidate molecule to the automated biochemical assay equipment; receiving of a set of possible drug candidates from a bioactivity module; performing of primary assays on the set of possible drug candidates; sending primary assay results to an artificial intelligence system for analysis; receiving a new drug candidate from a de novo ligand discovery module; performing of a secondary assay on the new drug candidate; and outputting a result of the secondary assay; receiving the assay procedures; generating a set of possible drug candidates based on the assay procedures; and sending chemical notation for the set of possible drug candidates to the automated biochemical assay equipment for performance of primary assays; receiving the primary assay result, the drug candidate molecule, and the binding site from the chemical database; performing one or more interpolations or perturbations of the drug candidate molecule to generate a new drug candidate molecule predicted to meet or exceed the first parameter, the prediction being based on the known interactions of ligands with protein binding sites from the chemical database; and sending chemical notation for the new drug candidate molecule to a retrosynthesis system operating on the computing device; receiving the chemical notation for the new drug candidate molecule; performing retrosynthesis of the new drug candidate molecule using rules for retrosynthesis of molecules stored in the chemical database; and sending to the chemical synthesizer chemical notation for precursors and synthesis steps for synthesizing the new drug candidate molecule. Claim 7: using automated biochemical assay equipment comprising an iterative physical testing system, perform the steps of: receiving an amount of a drug candidate molecule and an assay procedure, the assay procedure comprising a first parameter; automatically performing an assay of the drug candidate molecule according to the assay procedure to produce an assay result, the assay result comprising an indication as to whether the first parameter has been met by the drug candidate molecule; and where the assay result indicates that the first parameter has been met, sending the assay result for that assay to a bioactivity module along with chemical notation for the drug candidate molecule and a binding site; using a chemical synthesizer, performing the steps of: synthesizing a new drug candidate molecule from a supply of chemicals using chemical notation of precursors and synthesis steps provided by a retrosynthesis system; and providing an amount of the new drug candidate molecule to the automated biochemical assay equipment; using a laboratory equipment orchestration software operating on a computing device to control the system using: a laboratory API module that communicates with the artificial intelligence assistance system, receives instructions from it, sends back the data and provides information about the available chemical libraries, chemical synthesis capabilities and resources; a laboratory workflow control module that receives instructions from the artificial intelligence assistance system through a laboratory API and defines experimental workflows that the roboticized laboratory will follow, the experimental workflows comprising: receipt of a set of possible drug candidates from a bioactivity module; performance of primary assays on the set of possible drug candidates; sending of primary assay results to an artificial intelligence system for analysis; receipt a new drug candidate from a de novo ligand discovery module; performance of a secondary assay on the new drug candidate; and outputting a result of the secondary assay; a laboratory equipment utilization planning module that receives instructions from the laboratory workflow control module and plans laboratory module use and resource allocation; a laboratory equipment controller that receives the instructions from the laboratory equipment utilization planning module and sends the instructions to the appropriate laboratory equipment modules: the biochemical assay and automated chemical synthesis modules; using a bioactivity module operating on the computing device to perform the steps of: receiving the assay procedures; generating a set of possible drug candidates based on the assay procedures; and sending chemical notation for the set of possible drug candidates to the automated biochemical assay equipment for performance of primary assays; using a de novo ligand discovery module operating on the computing device to perform the steps of: receiving the primary assay result, the drug candidate molecule, and the binding site from the chemical database; performing one or more interpolations or perturbations of the drug candidate molecule to generate a new drug candidate molecule predicted to meet or exceed the first parameter, the prediction being based on the known interactions of ligands with protein binding sites from the chemical database; and sending chemical notation for the new drug candidate molecule to a retrosynthesis system operating on the computing device; using a retrosynthesis system operating on the computing device to perform the steps of: receiving the chemical notation for the new drug candidate molecule; performing retrosynthesis of the new drug candidate molecule using rules for retrosynthesis of molecules stored in the chemical database; and sending to the chemical synthesizer chemical notation for precursors and synthesis steps for synthesizing the new drug candidate molecule. Claim 2 of the current application is found in claim 1 of ‘885. Claim 3 of the current application corresponds to claim 2 of ‘885. Claim 4 of the current application corresponds to claim 3 of ‘885. Claim 5 of the current application corresponds to claim 4 of ‘885. Claim 6 of the current application corresponds to claim 5 of ‘885. Claim 7 of the current application corresponds to claim 6 of ‘885. Claim 9 of the current application corresponds to claim 8 of ‘885. Claim 10 of the current application corresponds to claim 9 of ‘885. Claim 11 of the current application corresponds to claim 10 of ‘885. Claim 12 of the current application corresponds to claim 11 of ‘885. Claim 13 of the current application corresponds to claim 12 of ‘885. Allowable Subject Matter Claims 1-13 would be allowed provided the 35 USC 112(b) and Double Patenting Rejections are overcome. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARLOTTE M BAKER whose telephone number is (571)272-7459. The examiner can normally be reached Mon - Fri 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JENNIFER MEHMOOD can be reached at (571)272-2976. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARLOTTE M BAKER/Primary Examiner, Art Unit 2664 06 October 2026
Read full office action

Prosecution Timeline

Mar 10, 2025
Application Filed
Oct 08, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12784273
APPARATUS AND METHOD FOR ESTIMATING USER POSE IN THREE-DIMENSIONAL SPACE
2y 9m to grant Granted Nov 03, 2026
Patent 12783187
PRINTER, NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM STORING COMPUTER-READABLE INSTRUCTIONS FOR PRINTER, AND METHOD EXECUTED BY PRINTER
2y 7m to grant Granted Nov 03, 2026
Patent 12786332
MANAGEMENT APPARATUS, CONTROL METHOD FOR MANAGEMENT APPARATUS, AND STORAGE MEDIUM
2y 6m to grant Granted Nov 03, 2026
Patent 12776121
SAMPLE-ADAPTIVE 3D FEATURE CALIBRATION AND ASSOCIATION AGENT
2y 10m to grant Granted Oct 27, 2026
Patent 12776025
METHOD AND SYSTEM FOR ANOMALY-BASED DEFECT INSPECTION
2y 9m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
93%
Grant Probability
93%
With Interview (+0.4%)
2y 0m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1104 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month